MedTrace Logo

Efficacy and Safety of Xinglou Chengqi Granule for Acute Ischemic Stroke

NCT07163702 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-09

No results posted yet for this study

Summary

This is a Ⅱa clinical trial. The purpose of this study is to preliminarily explore the optimal dosage of Xinglou Chengqi Granules in the treatment of acute ischemic stroke and to evaluate the efficacy and safety of Xinglou Chengqi Granules for acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

High-dose Xinglou Chengqi granules

Patients will receive orally high-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

DRUG

Low-dose Xinglou Chengqi granules and placebo

Patients will receive orally low-dose Xinglou Chengqi granules, combined with guidelines-based standard care.

Sponsors & Collaborators

  • Dongzhimen Hospital, Beijing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07163702 on ClinicalTrials.gov